Fidelity Investments’s CASI Pharmaceuticals CASI Stock Holding History

Fidelity Investments’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500	Closed	-$1.8K	–	5395
2024 Q1	$1.8K	Buy	+500	New	+$2.69K	﹤0.01%	4713
2021 Q2	–	Sell	-55	Closed	-$1K	–	4286
2021 Q1	$1K	Buy	55 +54	+5,400%	+$1.52K	﹤0.01%	3806
2020 Q4	$0	Buy	+1	New	+$22	﹤0.01%	3850
2019 Q4	–	Sell	-90	Closed	-$3K	–	3804
2019 Q3	$3K	Buy	90 +86	+2,150%	+$2.76K	﹤0.01%	3476
2019 Q2	$0	Buy	+4	New	+$128	﹤0.01%	3758
2018 Q4	–	Sell	-8	Closed	–	–	3554
2018 Q3	$0	Buy	+8	New	+$558	﹤0.01%	3528

Other funds holding CASI

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCM

Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments's CASI Position: Q2 2024 in Review

Fidelity Investments sold out of CASI Pharmaceuticals (CASI) in Q2 2024, closing a stake of 500 shares — an estimated $1.8K sold.

Fidelity Investments first reported a position in CASI in Q3 2018 and held it in 6 quarters. The position peaked at $3K in Q3 2019. 23 funds tracked by Wall St. Rank hold CASI as of Q2 2024.

Fidelity Investments reported no remaining CASI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Fidelity Investments sold 500 CASI Pharmaceuticals shares in Q2 2024, an estimated $1.8K.
Fidelity Investments first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Fidelity Investments's CASI Pharmaceuticals position peaked at $3K in Q3 2019.
23 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.